A review on newly approved PARP inhibitors: Talazoparib and Olaparib
This project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024.
1. Verfasser: | Karim, Azrin |
---|---|
Weitere Verfasser: | Islam, Farzana |
Format: | Project report |
Sprache: | English |
Veröffentlicht: |
Brac University
2024
|
Schlagworte: | |
Online Zugang: | http://hdl.handle.net/10361/24372 |
Ähnliche Einträge
-
A review on potential of PARP inhibitors in the treatment of prostate cancer
von: Islam, Saidul
Veröffentlicht: (2022) -
Association of XRCC1 and XPD polymorphism with risk of prostate cancer in Bangladesh population
von: Ahmed, Nafisa
Veröffentlicht: (2023) -
SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy
von: Meem, Manila
Veröffentlicht: (2023) -
Mutation in DNA polymerase γ: mitochondrial disorders
von: Hossain, Sadman Sanjid
Veröffentlicht: (2023) -
RIPK pathway, as a potential target, for cancer treatment - a review
von: Jahan, Nusrat
Veröffentlicht: (2024)